.: ORİJİNAL ARAŞTIRMA
The Effects of Resveratrol and Pioglitazone Treatment on Serum Resistin and Apelin Levels and Histochemical Parameters in the Metabolic Syndrome Rat Model: Animal Experiment
Rat Metabolik Sendrom Modelinde Resveratrol ve Pioglitazon Tedavisinin Serum Resistin ve Apelin Düzeyleri ile Histokimyasal Parametreler Üzerine Etkileri: Hayvan Deneyi
Turkiye Klinikleri J Med Sci. 2023;43(1):127-34
doi: 10.5336/medsci.2022-92225
Makale Dili: EN
Tam Metin
ABSTRACT
Objecvtive: The current research was aimed to determine the serum resistin and apelin levels in rats with metabolic syndrome and to examine the impact of resveratrol and pioglitazone intervention on serum resistin, apelin levels and metabolic parameters. Material and Methods: Fourty male Wistar albino rats were divided into 4 groups. Group 1 [n=10, control group; without (metabolic syndrome 'MetS')]; Group 2 (n=10, MetS group without treatment); Group 3 (n=10, MetS and treatment with resveratrol); Group 4 (n=10, MetS and treatment with pioglitazone). The rats were decapitated and resistin, apelin and biochemical parameters were studied in blood samples. Results: Apelin levels did not decreased in MetS+pioglitazone treatment group. Resistin level significantly decreased in treatment groups. Myxoid degeneration and edema in aortic vessel wall were less severe in MetS+resveratrol group. Periportal sinusoidal enlargement, congestion and lymphocyte infiltration in rat liver tissue with metabolic syndrome were absent in the group treated with resveratrol, and regressed in the group treated with pioglitazone treatment. Conclusion: Resistin and apelin concentrations have found to be increased in MetS and associated with insulin re- sistance. Although pioglitazone and resveratrol treat- ment decreased resistin levels, it was ineffective on apelin levels. Although pioglitazone treatment pro- vided improvement in histopathological changes, resveratrol treatment had more benefits on histopathological changes. In the treatment of metabolic syndrome, resveratrol may be useful in support therapy. This study is the first study which shows that pioglitazone does not effects the apelin levels in metabolic syndrome treatment
Keywords: Metabolic syndrome; resistin; apelin; resveratrol; pioglitazone
Objecvtive: The current research was aimed to determine the serum resistin and apelin levels in rats with metabolic syndrome and to examine the impact of resveratrol and pioglitazone intervention on serum resistin, apelin levels and metabolic parameters. Material and Methods: Fourty male Wistar albino rats were divided into 4 groups. Group 1 [n=10, control group; without (metabolic syndrome 'MetS')]; Group 2 (n=10, MetS group without treatment); Group 3 (n=10, MetS and treatment with resveratrol); Group 4 (n=10, MetS and treatment with pioglitazone). The rats were decapitated and resistin, apelin and biochemical parameters were studied in blood samples. Results: Apelin levels did not decreased in MetS+pioglitazone treatment group. Resistin level significantly decreased in treatment groups. Myxoid degeneration and edema in aortic vessel wall were less severe in MetS+resveratrol group. Periportal sinusoidal enlargement, congestion and lymphocyte infiltration in rat liver tissue with metabolic syndrome were absent in the group treated with resveratrol, and regressed in the group treated with pioglitazone treatment. Conclusion: Resistin and apelin concentrations have found to be increased in MetS and associated with insulin re- sistance. Although pioglitazone and resveratrol treat- ment decreased resistin levels, it was ineffective on apelin levels. Although pioglitazone treatment pro- vided improvement in histopathological changes, resveratrol treatment had more benefits on histopathological changes. In the treatment of metabolic syndrome, resveratrol may be useful in support therapy. This study is the first study which shows that pioglitazone does not effects the apelin levels in metabolic syndrome treatment
Keywords: Metabolic syndrome; resistin; apelin; resveratrol; pioglitazone
ÖZET
Amaç: Sunulan araştırmada, metabolik sendrom oluşturulan ratların serum rezistin ve apelin seviyelerinin incelenmesi ve resveratrol ve pioglitazon tedavisinin serum resistin, apelin düzeyleri ve metabolik parametreleri nasıl etkilediğinin araştırılması amaçlandı. Gereç ve Yöntemler: Kırk erkek Wistar albino rat 4 gruba ayrıldı. Grup 1 [n=10, kontrol grubu; (metabolik sendrom 'MetS') olmadan]; Grup 2 (n=10, tedavisiz MetS grubu); Grup 3 (n=10, MetS ve resveratrol ile tedavi); Grup 4 (n=10, MetS ve pioglitazon tedavisi). Ratlar dekapite edilerek, kan örneklerinde rezistin, apelin ve biyokimyasal parametreler çalışıldı. Bulgular: MetS+pioglitazon tedavi grubunda apelin seviyeleri düşmedi. Rezistin düzeyi tedavi gruplarında önemli ölçüde azaldı. Aort damar duvarında miksoid dejenerasyon ve ödem MetS+resveratrol grubunda daha az şiddetliydi. MetS'li sıçan karaciğer dokusunda periportal sinüzoidal genişleme, tıkanıklık ve lenfosit infiltrasyonu resveratrol ile tedavi edilen grupta yokken, pioglitazon tedavisi alan grupta geriledi. Sonuç: Resistin ve apelin konsantrasyonları MetS'de artmış ve insülin direnci ile ilişkili olduğu bulunmuştur. Pioglitazon ve resveratrol tedavisinin resistin düzeylerini düşürmesine karşın, apelin düzeyleri üzerine etkisisiz olduğu gösterilmiştir. Pioglitazon tedavisi histopatolojik değişikliklerde düzelme sağlasa da, resveratrol tedavisi histopatolojik değişiklikler üzerinde daha fazla fayda sağladığı gösterilmiştir. MetS tedavisinde resveratrolün destek tedavisinde faydalı olabiliceği düşünülmektedir. Bu çalışma, MetS tedavisinde pioglitazonun apelin düzeylerini etkilemediğini gösteren ilk çalışmadır.
Anahtar Kelimeler: Metabolik sendrom; resistin; apelin; resveratrol; pioglitazon
Amaç: Sunulan araştırmada, metabolik sendrom oluşturulan ratların serum rezistin ve apelin seviyelerinin incelenmesi ve resveratrol ve pioglitazon tedavisinin serum resistin, apelin düzeyleri ve metabolik parametreleri nasıl etkilediğinin araştırılması amaçlandı. Gereç ve Yöntemler: Kırk erkek Wistar albino rat 4 gruba ayrıldı. Grup 1 [n=10, kontrol grubu; (metabolik sendrom 'MetS') olmadan]; Grup 2 (n=10, tedavisiz MetS grubu); Grup 3 (n=10, MetS ve resveratrol ile tedavi); Grup 4 (n=10, MetS ve pioglitazon tedavisi). Ratlar dekapite edilerek, kan örneklerinde rezistin, apelin ve biyokimyasal parametreler çalışıldı. Bulgular: MetS+pioglitazon tedavi grubunda apelin seviyeleri düşmedi. Rezistin düzeyi tedavi gruplarında önemli ölçüde azaldı. Aort damar duvarında miksoid dejenerasyon ve ödem MetS+resveratrol grubunda daha az şiddetliydi. MetS'li sıçan karaciğer dokusunda periportal sinüzoidal genişleme, tıkanıklık ve lenfosit infiltrasyonu resveratrol ile tedavi edilen grupta yokken, pioglitazon tedavisi alan grupta geriledi. Sonuç: Resistin ve apelin konsantrasyonları MetS'de artmış ve insülin direnci ile ilişkili olduğu bulunmuştur. Pioglitazon ve resveratrol tedavisinin resistin düzeylerini düşürmesine karşın, apelin düzeyleri üzerine etkisisiz olduğu gösterilmiştir. Pioglitazon tedavisi histopatolojik değişikliklerde düzelme sağlasa da, resveratrol tedavisi histopatolojik değişiklikler üzerinde daha fazla fayda sağladığı gösterilmiştir. MetS tedavisinde resveratrolün destek tedavisinde faydalı olabiliceği düşünülmektedir. Bu çalışma, MetS tedavisinde pioglitazonun apelin düzeylerini etkilemediğini gösteren ilk çalışmadır.
Anahtar Kelimeler: Metabolik sendrom; resistin; apelin; resveratrol; pioglitazon
REFERANSLAR:
- Karaman ME, Tektemur A. The therapeutic effects of distinct exercise types on metabolic syndrome-induced reproductive system impairment in male rats: Potential contribution of mitochondria-related genes. Andrologia. 2022;54(4):e14391. [Crossref] [PubMed]
- Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12. [Crossref] [PubMed] [PMC]
- Lemieux I, Després JP. Metabolic syndrome: past, present and future. Nutrients. 2020;12(11):3501. [Crossref] [PubMed] [PMC]
- Feijóo-Bandín S, Aragón-Herrera A, Mora-a-Fernández S, Anido-Varela L, Tarazón E, Roselló-Lletí E, et al. Adipokines and Inflammation: Focus on Cardiovascular Diseases. Int J Mol Sci. 2020;21(20):7711. [Crossref] [PubMed] [PMC]
- Bongrani A, Mellouk N, Rame C, Cornuau M, Guérif F, Froment P, et al. Ovarian expression of adipokines in polycystic ovary syndrome: a role for chemerin, omentin, and apelin in follicular growth arrest and ovulatory dysfunction? Int J Mol Sci. 2019;20(15):3778. [Crossref] [PubMed] [PMC]
- da Fonseca Cardoso LM, de Souza Monnerat JA, de Medeiros Silva IWS, da Silva Ferreira Fiochi R, da Matta Alvarez Pimenta N, Mota BF, et al. Beverages rich in resveratrol and physical activity attenuate metabolic changes induced by high-fat diet. J Am Coll Nutr. 2021;40(6):485-95. [Crossref] [PubMed]
- Samsamshariat SZA, Sakhaei F, Salehizadeh L, Keshvari M, Asgary S. Relationship between resistin, endothelin-1, and flow-mediated dilation in patient with and without metabolic syndrome. Adv Biomed Res. 2019;8:16. [Crossref] [PubMed] [PMC]
- Emamalipour M, Seidi K, Jahanban-Esfahlan A, Jahanban-Esfahlan R. Implications of resistin in type 2 diabetes mellitus and coronary artery disease: Impairing insulin function and inducing pro-inflammatory cytokines. J Cell Physiol. 2019;234(12):21758-69. [Crossref] [PubMed]
- Onalan E, Yakar B, Barım AO, Gursu MF. Serum apelin and resistin levels in patients with impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, and metabolic syndrome. Endokrynol Pol. 2020;71(4):319-24. [Crossref] [PubMed]
- Sabry MM, Dawood AF, Rashed LA, Sayed SM, Hassan S, Younes SF. Relation between resistin, PPAR-γ, obesity and atherosclerosis in male albino rats. Arch Physiol Biochem. 2020;126(5):389-98. [Crossref] [PubMed]
- Asgary S, SamsamShariat SZ, Ghorbani A, Keshvari M, Sahebkar A, Sarrafzadegan N. Relationship between serum resistin concentrations with metabolic syndrome and its components in an Iranian population. Diabetes Metab Syndr. 2015;9(4):266-70. [Crossref] [PubMed]
- Gigante A, Iannazzo F, Navarini L, Sgariglia MC, Margiotta DPE, Vaiarello V, et al. Metabolic syndrome and adipokine levels in systemic lupus erythematosus and systemic sclerosis. Clin Rheumatol. 2021;40(10):4253-8. [Crossref] [PubMed] [PMC]
- Ochiai A, Othman MB, Sakamoto K. Kaempferol ameliorates symptoms of metabolic syndrome by improving blood lipid profile and glucose tolerance. Biosci Biotechnol Biochem. 2021;85(10):2169-76. [Crossref] [PubMed]
- Kim JE, Kim JS, Jo MJ, Cho E, Ahn SY, Kwon YJ, et al. The roles and associated mechanisms of adipokines in development of metabolic syndrome. Molecules. 2022;27(2):334. [Crossref] [PubMed] [PMC]
- Guo L, Li Q, Wang W, Yu P, Pan H, Li P, et al. Apelin inhibits insulin secretion in pancreatic beta-cells by activation of PI3-kinase-phosphodiesterase 3B. Endocr Res. 2009;34(4):142-54. [Crossref] [PubMed]
- Al-Muzafar HM, Alshehri FS, Amin KA. The role of pioglitazone in antioxidant, anti-inflammatory, and insulin sensitivity in a high fat-carbohydrate diet-induced rat model of insulin resistance. Braz J Med Biol Res. 2021;54(8):e10782. [Crossref] [PubMed] [PMC]
- Sharma AM, Staels B. Review: peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab. 2007;92(2):386-95. [Crossref] [PubMed]
- Kjær TN, Ornstrup MJ, Poulsen MM, Stødkilde-Jørgensen H, Jessen N, Jørgensen JOL, et al. No beneficial effects of resveratrol on the metabolic syndrome: a randomized placebo-controlled clinical trial. J Clin Endocrinol Metab. 2017;102(5):1642-51. [Crossref] [PubMed]
- Akbari M, Tamtaji OR, Lankarani KB, Tabrizi R, Dadgostar E, Haghighat N, et al. The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2020;19(1):25. [Crossref] [PubMed] [PMC]
- Oh WY, Shahidi F. Antioxidant activity of resveratrol ester derivatives in food and biological model systems. Food Chem. 2018;261:267-73. [Crossref] [PubMed]
- Eseberri I, Lasa A, Churruca I, Portillo MP. Resveratrol metabolites modify adipokine expression and secretion in 3T3-L1 pre-adipocytes and mature adipocytes. PLoS One. 2013;8(5):e63918. [Crossref] [PubMed] [PMC]
- Kur?vietienė L, Stanevičienė I, Mongirdienė A, Bernatonienė J. Multiplicity of effects and health benefits of resveratrol. Medicina (Kaunas). 2016;52(3):148-55. [Crossref] [PubMed]
.: İşlem Listesi